MA-BOS-BIOMED/FACT-CRO
7.1.2019 12:02:06 CET | Business Wire | Press release
Factory-CRO Group , a leading global contract research organization (CRO) focused on medical devices and in vitro diagnostics (IVDs), and Boston Biomedical Associates (BBA) a premier full-service Medical Device/Biotechnology CRO and Consultancy based in the United States announce that they have merged the organizations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190107005358/en/
The merger further advances the shared strategic vision to become the leading Global Medical Device and Medical Technology focused CRO. Following the recent acquisitions of MileStone Research Organization, Five Corners, and Clinical Device Group the Factory-CRO Group now has specialized operations and expertise in the United States, Australia/New Zealand, and Europe. This global expansion coupled with the diverse medical therapeutic expertise provides a means to efficiently service clients.
“BBA is excited to join Factory-CRO’s worldwide group as it will allow us to expand our comprehensive service offering to our clients,” said Lauren Baker, PhD, President and CEO of BBA. “The alignment of Factory-CRO and BBA’s core values and approach to engagements combined with our collective therapeutic competencies ensures that our clients now have improved access to our global clinical trial execution resources, and our regulatory and medical expertise.” Dr. Baker then added, “We are able to fully support our clients as their needs evolve and they strive to help patients globally.”
“We are honored to have the BBA team join the Factory-CRO Group,” said Dirk Meijer, MD, MSc,PhD, Factory-CRO CEO. “BBA’s ability to provide CRO/Consultative service in North America was a missing link in our global offerings.” Dr. Meijer then added, “Our clients have consistently asked us to expand our offerings in North America. This merger allows us to provide our specialized expertise and a continued commitment to the highest level of customized service to a larger audience. Now we are the only Medical Device and Medical Technology CRO that offers services in United States, Europe, Australia and New Zealand. We operate from our own offices located within each region housed with employees that have refined expertise to meet our unique client needs.”
About Factory-CRO Group:
Factory-CRO
Group is a leading, full-service contract research organization focused
on the management of clinical studies for medical devices, IVDs,
biologics and device-drug combination products internationally. Founded
in 1992, the business offers a full suite of trial management services
to its global client base across a broad range of therapeutic areas,
including orthopedic, cardiovascular, dermatology and aesthetics.
Current members of Factory-CRO Group are: BBA, Five Corners CRO,
Milestone Research group and Factory-CRO.
For more information about Factory-CRO, visit their website, www.factory-cro.com or contact Joris Bannenberg, MD, PhD, Factory-CRO’s CMO:
Joris Bannenberg, MD, PhD
CMO
j.bannenberg@factory-cro.com
+31
30 229 2727 (x108)
About Boston Biomedical Associates:
Boston
Biomedical Associates (BBA) is a premier full-service Medical
Device/Biotechnology CRO and Consultancy firm. Founded in 2000, by
Lauren Baker, Ph.D., this leading CRO has earned a reputation for its
comprehensive approach to clinical trial execution services to its
global client base across a broad range of therapeutic areas, including
orthopedic, cardiovascular, endocrine and neurologic disorders.
For more information about BBA, visit their website, www.bbacro.com or contact Mack Rubley, PhD, BBA’s Vice President of Business Development and Marketing:
Mack D. Rubley, PhD
VP, Business Development and Marketing
702-808-3494
mrubley@bbacro.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190107005358/en/
Contact:
Joris Bannenberg, MD, PhD CMO j.bannenberg@factory-cro.com +31 30 229 2727 (x108)
Mack D. Rubley, PhD VP, Business Development and Marketing 702-808-3494 mrubley@bbacro.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering31.3.2026 19:01:00 CEST | Press release
Streamlines Hillside Technology testing across browsers and mobile devices while supporting rapid expansion into regulated markets. TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced that Hillside Technology Limited, the technology powerhouse behind global online gambling leader bet365, has adopted its platform to unify software testing and support hundreds of weekly production releases. The global online gaming industry is currently experiencing a massive shift, with the market projected to exceed $150 billion by 2030. As mobile gaming becomes the primary touchpoint for users, the technical complexity of delivering a seamless, low-latency experience has grown exponentially. For industry giants like bet365, the need to validate software across an infinite matrix of hardware, screen resolutions, and OS versions is a mission-critical requirement. This partnership ensures that, as gaming becomes more mobile-centric, bet36
IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand31.3.2026 16:00:00 CEST | Press release
Regulatory milestone opens heart health growth opportunities for food and beverage manufacturers IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330523416/en/ First heart health claim approved for soy protein in Australia and New Zealand. “For decades, IFF has invested in the science behind soy protein and its role in supporting cardiovascular health,” said Tony Andrew, vice president of protein solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ing
Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care31.3.2026 15:26:00 CEST | Press release
Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue to develop its novel bionic lymph node technology designed to transform how lymphedema is managed, based on scientific innovations from the Weizmann Institute and Shamir Medical Center. The system aims to provide a solution to manage fluid with a subcutaneous implant that will allow patients freedom of movement, automatic fluid management and reduction of symptoms such as pain and swelling. Lymphedema affects millions of patients worldwide, especially breast cancer survivors, and remains significantly under
HTEC Achieves SOC 2 Type II Attestation, Reinforcing Commitment to Client Trust31.3.2026 15:25:00 CEST | Press release
HTECtoday announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331132225/en/ HTEC today announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. For clients, this means working with a technology partner whose practices are standardized, consistently executed, and independently verified over time. It reflects a level of operational maturity where security, reliability, and data protection are built into every engagement. Achieving this standard required coordinated effort across the entire organization. Compliance, engineering, delivery, security, IT, legal, and people t
Impartner Redefines Partner Marketing Automation with Full Automation, AdTech and AI to Drive Measurable Revenue31.3.2026 15:00:00 CEST | Press release
New automation and AI capabilities connect partner campaigns and engagement directly to pipeline and revenue outcomes. Impartner, the world’s leading partner revenue orchestration platform, today announced a major advancement that unifies partner marketing automation within the platform, powered by full automation, AdTech and AI to turn partner marketing into measurable revenue. As partner ecosystems expand across regions, marketplaces and multi-tier models, marketing execution has often remained fragmented. Impartner eliminates those gaps by unifying recruitment, enablement, campaign automation and performance tracking within a single operational system, making partner demand generation and marketing fully operational, measurable, and scalable across all partner interactions. “What makes partner marketing successful is not content distribution, it’s execution, scale and measurable pipeline and revenue,” said Emile van de Klok, Senior Director of Channel Marketing Solutions at Impartne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom